Editas Medicine, Inc. (FRA:8EM)

Editas Medicine Statistics

Total Valuation

Editas Medicine has a market cap or net worth of EUR 183.90 million. The enterprise value is 58.31 million.

Market Cap	183.90M
Enterprise Value	58.31M

Important Dates

The next estimated earnings date is Thursday, March 5, 2026.

Earnings Date	Mar 5, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	97.62M
Shares Outstanding	n/a
Shares Change (YoY)	+3.57%
Shares Change (QoQ)	+6.73%
Owned by Insiders (%)	0.36%
Owned by Institutions (%)	45.05%
Float	97.27M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.65
PB Ratio	16.04
P/TBV Ratio	16.04
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-0.34
EV / Sales	1.46
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.38

Financial Position

The company has a current ratio of 2.86, with a Debt / Equity ratio of 1.46.

Current Ratio	2.86
Quick Ratio	2.81
Debt / Equity	1.46
Debt / EBITDA	n/a
Debt / FCF	-0.11
Interest Coverage	-18.04

Financial Efficiency

Return on equity (ROE) is -211.37% and return on invested capital (ROIC) is -60.51%.

Return on Equity (ROE)	-211.37%
Return on Assets (ROA)	-28.26%
Return on Invested Capital (ROIC)	-60.51%
Return on Capital Employed (ROCE)	-85.50%
Revenue Per Employee	160,700
Profits Per Employee	-692,355
Employee Count	246
Asset Turnover	0.18
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -0.39% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-0.39%
50-Day Moving Average	2.72
200-Day Moving Average	2.03
Relative Strength Index (RSI)	33.84
Average Volume (20 Days)	1,653

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	4.08

Income Statement

In the last 12 months, Editas Medicine had revenue of EUR 39.53 million and -170.32 million in losses. Loss per share was -2.00.

Revenue	39.53M
Gross Profit	-55.21M
Operating Income	-102.00M
Pretax Income	-170.32M
Net Income	-170.32M
EBITDA	-95.49M
EBIT	-102.00M
Loss Per Share	-2.00

Balance Sheet

The company has 141.18 million in cash and 16.75 million in debt, giving a net cash position of 124.43 million.

Cash & Cash Equivalents	141.18M
Total Debt	16.75M
Net Cash	124.43M
Net Cash Per Share	n/a
Equity (Book Value)	11.47M
Book Value Per Share	0.12
Working Capital	98.12M

Cash Flow

In the last 12 months, operating cash flow was -153.09 million and capital expenditures -926,450, giving a free cash flow of -154.01 million.

Operating Cash Flow	-153.09M
Capital Expenditures	-926,450
Free Cash Flow	-154.01M
FCF Per Share	n/a

Margins

Gross Margin	-139.66%
Operating Margin	-258.03%
Pretax Margin	-430.84%
Profit Margin	n/a
EBITDA Margin	-241.55%
EBIT Margin	-258.03%
FCF Margin	n/a

Dividends & Yields

Editas Medicine does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.57%
Shareholder Yield	-3.57%
Earnings Yield	-92.62%
FCF Yield	-83.75%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Editas Medicine has an Altman Z-Score of -11.73 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-11.73
Piotroski F-Score	3